These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22722717)

  • 21. Safety and efficacy of drug-eluting bead chemoembolization for hepatocellular carcinoma: comparison of small-versus medium-size particles.
    Padia SA; Shivaram G; Bastawrous S; Bhargava P; Vo NJ; Vaidya S; Valji K; Harris WP; Hippe DS; Kogut MJ
    J Vasc Interv Radiol; 2013 Mar; 24(3):301-6. PubMed ID: 23380737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads.
    Guiu B; Deschamps F; Aho S; Munck F; Dromain C; Boige V; Malka D; Leboulleux S; Ducreux M; Schlumberger M; Baudin E; de Baere T
    J Hepatol; 2012 Mar; 56(3):609-17. PubMed ID: 22027582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
    Wu B; Zhou J; Ling G; Zhu D; Long Q
    World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
    Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
    Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
    Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
    Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multicentre prospective study of drug-eluting bead chemoembolisation safety using tightly calibrated small microspheres in non-resectable hepatocellular carcinoma.
    Urbano J; Echevarria-Uraga JJ; Ciampi-Dopazo JJ; Sánchez-Corral JA; Cobos Alonso J; Anton-Ladislao A; Peña-Baranda B; Nacarino-Mejias V; González-Costero R; Muñoz Ruiz-Canela JJ; Pérez-Cuesta J; Lanciego C; de Gregorio MA
    Eur J Radiol; 2020 May; 126():108966. PubMed ID: 32278280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liver abscess after drug-eluting bead chemoembolization in patients with metastatic hepatic tumors.
    Ye T; Zhu P; Liu Z; Ren Q; Zheng C; Xia X
    Br J Radiol; 2022 Jan; 95(1129):20211056. PubMed ID: 34762523
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial.
    Vogl TJ; Lammer J; Lencioni R; Malagari K; Watkinson A; Pilleul F; Denys A; Lee C
    AJR Am J Roentgenol; 2011 Oct; 197(4):W562-70. PubMed ID: 21940527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemoembolization of unresectable hepatocellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol.
    Recchia F; Passalacqua G; Filauri P; Doddi M; Boscarato P; Candeloro G; Necozione S; Desideri G; Rea S
    Oncol Rep; 2012 May; 27(5):1377-83. PubMed ID: 22294036
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of Response to Transcatheter Arterial Chemoembolization with Doxorubicin-eluting Microspheres: Tumor Biology and Hepatocellular Carcinoma Recurrence in a 5-year Transplant Cohort.
    Sandow TA; Arndt SE; Albar AA; DeVun DA; Kirsch DS; Gimenez JM; Bohorquez HE; Gilbert PJ; Thevenot PT; Nunez KG; Galliano GA; Cohen AJ; Kay D; Gulotta PM
    Radiology; 2018 Mar; 286(3):1072-1083. PubMed ID: 29206595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
    Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
    J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial Treatment of Unresectable Neuroendocrine Tumor Liver Metastases with Transarterial Chemoembolization using Streptozotocin: A 20-Year Experience.
    Dhir M; Shrestha R; Steel JL; Marsh JW; Tsung A; Tublin ME; Amesur NB; Orons PD; Santos E; Geller DA
    Ann Surg Oncol; 2017 Feb; 24(2):450-459. PubMed ID: 27663565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial.
    Chen JX; Wileyto EP; Soulen MC
    Trials; 2018 Jul; 19(1):390. PubMed ID: 30016989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
    Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
    Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.
    Albrecht KC; Aschenbach R; Diamantis I; Eckardt N; Teichgräber U
    J Cancer Res Clin Oncol; 2021 Jan; 147(1):23-32. PubMed ID: 32880029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
    Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
    J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intraprocedural C-arm dual-phase cone-beam CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma?
    Loffroy R; Lin M; Yenokyan G; Rao PP; Bhagat N; Noordhoek N; Radaelli A; Blijd J; Liapi E; Geschwind JF
    Radiology; 2013 Feb; 266(2):636-48. PubMed ID: 23143027
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma.
    Malagari K; Pomoni M; Kelekis A; Pomoni A; Dourakis S; Spyridopoulos T; Moschouris H; Emmanouil E; Rizos S; Kelekis D
    Cardiovasc Intervent Radiol; 2010 Jun; 33(3):541-51. PubMed ID: 19937027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
    Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
    BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center.
    Luz JH; Luz PM; Martin HS; Gouveia HR; Levigard RB; Nogueira FD; Rodrigues BC; de Miranda TN; Mamede MH
    Cancer Imaging; 2017 Feb; 17(1):5. PubMed ID: 28166821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.